Trials / Completed
CompletedNCT00539760
A Phase I Rheumatoid Arthritis Study in Healthy Volunteers
A Phase I, Randomized, Observer- and Subject-Blind, Placebo-Controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1827771 in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
GSK182771 is a domain antibody targeting the interleukin (IL)-1 receptor which is being developed for the treatment of rheumatoid arthritis. This study is being done in healthy volunteers to verify the safety and tolerability of GSK182771
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK1827771 | GSK1827771 will be administered using injection via subcutaneous (SC) route. |
| DRUG | Placebo | Placebo to GSK1827771 for Injection will be administered via SC route |
Timeline
- Start date
- 2007-09-05
- Primary completion
- 2008-04-05
- Completion
- 2008-04-05
- First posted
- 2007-10-05
- Last updated
- 2017-08-15
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00539760. Inclusion in this directory is not an endorsement.